Childhood acute myeloid leukaemia (AML) is characterized by a relevant cytogenetic and molecular heterogeneity. The past few decades have seen significant improvements in its biological characterization and subsequent risk assessment, with an increasingly molecularly‐refined definition of specific subgroups (Pui *et al*, [2011](#bjh15725-bib-0034){ref-type="ref"}; Zwaan *et al*, [2015](#bjh15725-bib-0044){ref-type="ref"}). The advent of large‐scale genomic sequencing technologies has greatly improved the molecular classification of AML and enabled the identification of a subset of paediatric AML associated with a dismal outcome even when high‐intensity therapies, including allogeneic haematopoietic stem cell transplantation (allo‐HSCT), are employed. This is the case for AML carrying the cryptic inversion of chromosome 16 leading to the *CBFA2T3*‐*GLIS2* fusion gene, recently reported in exclusively paediatric settings and unanimously recognized as a type of leukaemia associated with a grim prognosis (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}). The identification of this fusion gene is due to the tremendous effort made in the characterization through RNA and exome sequencing of non‐Down syndrome acute megakaryoblastic leukaemia (non‐DS‐AMKL) (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; De Rooij *et al*, [2013](#bjh15725-bib-0008){ref-type="ref"}, [2017](#bjh15725-bib-0010){ref-type="ref"}). Indeed, RNA and exome sequencing allowed the description of recurrent and mutually‐exclusive chimeric gene fusions associated with paediatric AMKL that are found in around 60% of cases, including *RBM15‐MRTFA* (*MKL1*), *CBFA2T3‐GLIS2*,*NUP98‐KDM5A* and *KMT2A* (*MLL*) rearrangements (Fig [1](#bjh15725-fig-0001){ref-type="fig"}) (Gruber & Downing, [2015](#bjh15725-bib-0015){ref-type="ref"}; De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}, [2017](#bjh15725-bib-0010){ref-type="ref"}). *CBFA2T3‐GLIS2* is the most frequently identified chimeric oncogene to date in this subset of patients (Gruber & Downing, [2015](#bjh15725-bib-0015){ref-type="ref"}). Due to the cryptic nature of the *CBFA2T3‐GLIS2* fusion, this lesion not identifiable by morphology and cytogenetics (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). The molecular bases for transformation by *CBFA2T3‐GLIS2* are still unclear; patients carrying this molecular lesion present with a low mutational burden compared with other AML patients (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}), thus suggesting that this fusion gene probably represents the founder and sole genomic alteration.

![Frequency of the most commonly chimeric gene fusions associated with paediatric non‐DS‐AMKL.](BJH-184-337-g001){#bjh15725-fig-0001}

Although *CBFA2T3‐GLIS2* transcript is present in almost 20% of paediatric non‐DS‐AMKL, it seems not to be exclusively restricted to the French‐American‐British (FAB) M7 subgroup (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). However, the peculiarity of leukaemia carrying this chimeric oncogene goes beyond the considerable incidence in specific subgroups of children with AML, or the association with a poor prognosis. This lesion seems to distinguish a specific biological and clinical subtype of leukaemia, with intriguing mechanisms driving leukaemogenesis (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}), singular morphological and immunophenotype features, and clinical behaviour.

We here review recent evidence that has emerged over the last few years regarding *CBFA2T3*‐*GLIS2*‐positive AML, providing a comprehensive and detailed clinical and biological picture of this entity.

Incidence {#bjh15725-sec-0002}
=========

The *CBFA2T3‐GLIS2* fusion gene was initially reported to occur only in the paediatric non‐DS‐AMKL subgroup (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}). As already mentioned, this is the most frequent chimeric oncogene identified in this subset of patients. In a cohort including 22 non‐DS paediatric AMKL, 9 DS AMKL and 8 adult AMKL cases, Thiollier *et al* ([2012](#bjh15725-bib-0037){ref-type="ref"}) first identified the presence of the fusion gene in 31% (*N* = 7) of non‐DS paediatric AMKL patients, a fusion never detected in DS‐AMKL and adult AMKL patients. In an almost concomitant report, Gruber *et al* ([2012](#bjh15725-bib-0016){ref-type="ref"}) performed transcriptome sequencing on leukaemia cells collected at diagnosis from a discovery cohort of 14 paediatric non‐DS‐AMKL cases and a recurrence/validation cohort of 34 paediatric and 28 adult non‐DS‐AMKL cases. *CBFA2T3‐GLIS2* fusion was found in 13 of 48 paediatric samples (27%), confirming that this lesion is restricted to the paediatric population. Our group identified the *CBFA2T3‐GLIS2* fusion gene in 20 of 237 patients with cytogenetically normal (CN) AML (8·4%). Among the positive cases, only a half belonged to FAB M7 subgroup, the remaining cases were associated with other morphological FAB subgroups, such as M0, M1, M2, M4 and M5 AML (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). In the two largest cohorts of paediatric AMKL screened by deep‐sequencing approaches and collected thanks to international collaborative efforts, the presence of the *CBFA2T3‐GLIS2* fusion gene was detected in 16% and 18·6% of cases (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}, [2017](#bjh15725-bib-0010){ref-type="ref"}). Recently, a higher percentage (27%) of transcript‐positive patients was reported in paediatric non‐DS‐AMKL enrolled in two Japanese clinical trials, whilst it was not identified in any of the other paediatric AML cases studied (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}).

Molecular structure of *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0003}
==================================================

The chimeric transcript involving *CBFA2T3* and *GLIS2* results from a cryptic inversion of the telomeric region of chromosome 16 that fuses the 5′ portion of *CBFA2T3* in frame with the 3′ region of *GLIS2*. The most common chimeric *CBFA2T3‐GLIS2* transcript lies between exon 11 of *CBFA2T3* and exon 3 of *GLIS2* (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}) (Fig [2](#bjh15725-fig-0002){ref-type="fig"}). Other rare chimeric transcripts have been reported: *CBFA2T3‐*ex10*/GLIS2‐*ex3 (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}), *CBFA2T3‐*ex12*/GLIS2‐*ex1 (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}) and *CBFA2T3‐*ex10*/GLIS2‐*ex2 (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}).

![Representation of CBFA2T3‐GLIS2 fusion protein. Top panels: Common breakpoints in *CBFA2T3* and *GLIS2* genes at exons 11 and 3, respectively. Bottom panel: CBFA2T3‐Ex11/GLIS2‐Ex3 fusion protein with the retained domains. MYND, myeloid, nervy, and DEAF‐1; NHR, nervy homology regions; TAD, topologically associating domain; TRD, trans‐Repression Domain; ZF, zinc finger.](BJH-184-337-g002){#bjh15725-fig-0002}

CBFA2T3 is a member of the RUNX1T1 (previously termed ETO/CBFA2T1/MTG8) complex and was initially identified as a fusion partner of *RUNX1* in rare cases of therapy‐related AML harbouring t(16;21)(q24;q22) (Gamou *et al*, [1998](#bjh15725-bib-0013){ref-type="ref"}). Later, it was implicated in the maintenance of haematopoietic stem cell quiescence (Chyla *et al*, [2008](#bjh15725-bib-0004){ref-type="ref"}). In particular, CBFA2T3 participates in high‐molecular‐weight complexes and its expression is essential for haematopoietic stem cell self‐renewal and differentiation. Furthermore, it plays a critical role in the development of megakaryocyte‐erythrocyte progenitors *in‐vivo* (Fischer *et al*, [2012](#bjh15725-bib-0012){ref-type="ref"}; Leung *et al*, [2013](#bjh15725-bib-0024){ref-type="ref"}). The genomic structure and amino acid sequence of CBFA2T3 are highly similar to that of the other two CBFA2T‐family members (RUNX1T1, previously termed CBFA2T1, and CBFA2T2). In particular, CBFA2T2 is known to bind to the RUNX1/RUNX1T1 complex and its relevance in leukaemogenesis is reported in both paediatric and adult AML (Richkind *et al*, [2000](#bjh15725-bib-0035){ref-type="ref"}; Guastadisegni *et al*, [2010](#bjh15725-bib-0017){ref-type="ref"}; Bolouri *et al*, [2018](#bjh15725-bib-0003){ref-type="ref"}).

GLIS2 (GLI‐similar 2) is a member of the Krüppel‐like zinc finger transcription factor group, which is closely related to the GLI family of proteins mediating the transcriptional response to the Hedgehog pathway activation (Lamar *et al*, [2001](#bjh15725-bib-0023){ref-type="ref"}; Kim *et al*, [2007](#bjh15725-bib-0022){ref-type="ref"}). *GLIS2* is highly expressed in the adult kidney, where it suppresses the GLI1‐activated transcriptome and maintains homeostasis. *GLIS2* inactivating mutations have been found in nephronophthisis, an autosomal recessive renal disease (Attanasio *et al*, [2007](#bjh15725-bib-0002){ref-type="ref"}). Before 2012, *GLIS*2 had never been previously implicated in leukaemogenesis. Its pivotal role for haematopoietic stem cell repopulation in mice has been recently suggested (Holmfeldt *et al*, [2016](#bjh15725-bib-0020){ref-type="ref"}). However, it is not expressed in differentiating haematopoietic cells, suggesting that its fusion with *CBFA2T3* leads to ectopic *GLIS2* activity (Thirant *et al*, [2017b](#bjh15725-bib-0039){ref-type="ref"}).

Because of the fusion, CBFA2T3 loses the MYND (myeloid, nervy and Deaf‐1 domain) class of zinc finger domain reported to interact with the nuclear receptor co‐repressor (NCoR) repressor complex. In contrast, the *GLIS2* gene maintains the zinc finger domain and, consequently, the ability to interact with DNA (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}) (Fig [2](#bjh15725-fig-0002){ref-type="fig"}).

Gene expression profile {#bjh15725-sec-0004}
=======================

Patients with *CBFA2T3‐GLIS2* positive AML present a clearly peculiar expression signature clustering them apart from other non‐DS‐AMKL, including up‐regulation of genes involved in the Hedgehog, JAK‐STAT and wingless/integrated (WNT)/ß‐catenin pathways. In particular, analysis of the gene expression signatures of *CBFA2T3‐GLIS2* expressing AMKLs revealed altered expression of a number of genes in the sonic hedgehog (SHH) and WNT pathways, such as *GATA3*,*IGFBP7*,*CCND2*,*PTCH1* and *HHIP*, as well the bone morphogenic protein (BMP) pathway *BMP2* and *BMP4*, which is directly influenced by SHH signalling (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}). In an elegant series of experiments, Thirant *et al* ([2017a](#bjh15725-bib-0038){ref-type="ref"}) recently elucidated the transcriptional programme and unique functional properties induced by *CBFA2T3‐GLIS2* in the leukaemogenesis‐driving process. To define the effect of *CBFA2T3‐GLIS2* and the contribution of *CBFA2T3* and *GLIS2* moieties to haematopoietic differentiation and self‐renewal, *CBFA2T3‐GLIS2*‐, *CBFA2T3*‐ or *GLIS2*‐encoding retroviruses have been transduced into murine bone marrow progenitors and *in‐vitro* cultures were performed. The expression of *GLIS2* or *CBFA2T3‐GLIS2* induced megakaryocytic differentiation in primary haematopoietic progenitor cells, but only *CBFA2T3‐GLIS2* resulted in increased self‐renewal capacity. Furthermore, the ectopic expression of *CBFA2T3*,*GLIS2* or *CBFA2T3‐GLIS2* in the HEL cell line identified 3,798 differentially expressed genes significantly correlated with a published *CBFA2T3‐GLIS2* patient signature and contained most of the genes regulated by *CBFA2T3* (*n* = 1125) or *GLIS2* (*n* = 1173), while 2405 genes were specifically deregulated by the *CBFA2T3‐GLIS2* fusion. Interestingly, several transcription factors known to interact with CBFA2T3 were down‐regulated by the fusion transcript, including *GATA1* (−9‐fold), while the megakaryocytic oncogene *ERG* was up‐regulated upon *CBFA2T3*‐*GLIS2* and *GLIS2* expression (+9·44‐ and +2·88‐fold, respectively).

Chromatin immunoprecipitation (ChIP) sequencing demonstrated that the fusion transcript binds CBFA2T3 known sites. Moreover, ChIP experiments confirmed that the fusion transcript interacts with motifs of factors known to complex with CBFA2T3, including those for RUNX1, ERG and GATA1. Interestingly, *de novo* binding sites tended to be located in super‐enhancer regions and to be co‐occupied by ERG and these sites are associated with strong up‐regulation. As a result, the *CBFA2T3‐GLIS2* gene blocks in a unique hit the differentiation of megakaryocytic cells, inhibiting the expression of *GATA1*, and increases self‐renewal capacity by inducing the expression of *ERG* (Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}) (Fig [3](#bjh15725-fig-0003){ref-type="fig"}). Based on this evidence, targeting integrity of the CBFA2T3‐GLIS2 complex may represent an appealing opportunity for developing targeted therapeutic strategies (Thirant *et al*, [2017b](#bjh15725-bib-0039){ref-type="ref"}).

![Mechanism of action of the CBFA2T3‐GLIS2 fusion protein. CBFA2T3‐GLIS2 is a part of a complex that binds to both promotor and enhancer sequences of many genes. In particular, it up‐regulates ERG and KIT expression and it down‐regulates GATA1 expression (Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}). Therefore, the fusion protein in one hit induces a block of differentiation and increases self‐renewal of haematopoietic cells driving leukaemia development.](BJH-184-337-g003){#bjh15725-fig-0003}

Mutation pattern in *CBFA2T3‐GLIS2* positive leukaemia {#bjh15725-sec-0005}
======================================================

Despite the poor prognosis and low response to conventional chemotherapy, transplantation of fusion gene‐modified bone marrow cells into animal syngeneic recipients failed to induce overt leukaemia transformation, consistent with a requirement for cooperative mutations (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Dang *et al*, [2017](#bjh15725-bib-0007){ref-type="ref"}).

However, the total burden of somatic mutations associated with *CBFA2T3‐GLIS2* is significantly lower than that found in other subgroups of AMKL (7·17 ± 3·60 vs. 16·60 ± 5·13, *P* = 0·009) (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}). Indeed, genetic mutations involving *GATA1*,*KIT* and *FLT3* genes are less frequent in *CBFA2T3‐GLIS2*‐positive than in negative patients, being detected only in few cases. In the study reported by Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"}), genetic mutations were found in 14% of AMKL *CBFA2T3‐GLIS2*‐positive patients as compared to 35% of negative patients. The genes commonly involved are *FLT3*,*GATA1* and *KIT* (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}) as well as *RAS* mutations and mutations in the JAK/STAT pathway (Table [1](#bjh15725-tbl-0001){ref-type="table"}) (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}). So far, an impact of the mutation burden on the outcome of CBFA2T3‐GLIS2 positive AML has not been demonstrated.

###### 

Frequency of cooperating mutations in *CBFA2T3‐GLIS2* positive leukaemia in comparison with other subgroups of paediatric AML

  Aberration   *CBFA2T3‐GLIS2* positive AML   *CBFA2T3‐GLIS2* negative AML                            References
  ------------ ------------------------------ ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *FLT3*       17%                            7--10%                                                  Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"}); Meshinchi *et al* ([2006](#bjh15725-bib-0031){ref-type="ref"}); Bolouri *et al* ([2018](#bjh15725-bib-0003){ref-type="ref"}); Manara *et al* ([2017](#bjh15725-bib-0026){ref-type="ref"})
  *JAK/STAT*   13--23%                        15%[\*](#bjh15725-note-0003){ref-type="fn"}             Gruber *et al* ([2012](#bjh15725-bib-0016){ref-type="ref"}); De Rooij *et al* ([2017](#bjh15725-bib-0010){ref-type="ref"})
  *RAS*        6%                             17--19%                                                 De Rooij *et al* ([2017](#bjh15725-bib-0010){ref-type="ref"}); Goemans *et al* ([2005](#bjh15725-bib-0014){ref-type="ref"}); Bolouri *et al* ([2018](#bjh15725-bib-0003){ref-type="ref"})
  *GATA1*      17%                            7--9%[\*](#bjh15725-note-0003){ref-type="fn"}           Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"}); Gruber *et al* (2015); De Rooij *et al* ([2017](#bjh15725-bib-0010){ref-type="ref"})
  *KIT*        8%                             44%[†](#bjh15725-note-0004){ref-type="fn"} of CBF‐AML   Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"}); Manara *et al* ([2014](#bjh15725-bib-0025){ref-type="ref"})

AML, acute myeloid leukaemia; CBF, core‐binding factor; non‐DS‐AMKL, non‐Down syndrome acute megakaryoblastic leukaemia.

The percent is restricted to non‐DS‐AMKL.

The percent is restricted to paediatric CBF‐AML (inv(16), t(16;16), t(8;21)).

John Wiley & Sons, Ltd

Cytogenetic pattern of abnormalities in *CBFA2T3‐GLIS2* positive leukaemia {#bjh15725-sec-0006}
==========================================================================

Concomitant cytogenetic abnormalities are rare in patients expressing *CBFA2T3‐GLIS2*. In the Japanese cohort, 33% of fusion‐positive patients had a normal karyotype (i.e. CN‐AML) as compared to 9% in fusion‐negative patients (*P* = 0·075) (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}). When not associated with normal karyotype, *CBFA2T3‐GLIS2* was associated with trisomy 21 (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}), complex karyotype and hyperdiploidy, suggesting that the fusion oncogene can be found in patients with a variety of cytogenetic aberrations (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}).

By whole‐transcriptome sequencing, we recently identified a new fusion transcript in *CBFA2T3‐GLIS2‐*positive patients, involving Desert Hedgehog (*DHH*), a member of Hedgehog family, and Ras Homologue Enrich in Brain Like 1 (*RHEBL1*), a gene coding for a small GTPase of the Ras family (Masetti *et al*, [2013b](#bjh15725-bib-0028){ref-type="ref"}). We detected *DHH‐RHEBL1* fusion in 8 out of 20 (40%) *CBFA2T3‐GLIS2*‐rearranged patients. Gene expression analysis performed on RNA‐seq data revealed that *DHH‐RHEBL1*‐positive patients exhibited a specific signature (Masetti *et al*, [2013b](#bjh15725-bib-0028){ref-type="ref"}).

With regard to recurrent molecular abnormalities of non‐DS‐AMKL, the *CBFA2T3‐GLIS2* fusion gene is mutually exclusive with other cryptic chimeric fusion genes recurrently detected in this AML FAB variant, namely *RBM15‐MRTFA* and *NUP98‐KDM5A* (De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}).

Clinical characteristics of patients carrying the *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0007}
=============================================================================

Recent studies compared the clinical features of patients with and without *CBFA2T3‐GLIS2*, either belonging or not to the AMKL subgroup, to establish if the fusion gene confers a distinct clinical profile to these patients (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}). No significant differences in gender were found between the two groups (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}). Regarding age, as already mentioned, the *CBFA2T3‐GLIS2* fusion has never been found in adult AML patients (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}) and, in childhood, fusion‐positive patients have been found to be significantly younger than fusion‐negative patients (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}). In particular, most patients with *CBFA2T3‐GLIS2* were younger than 5 years of age (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Masetti *et al*, [2014](#bjh15725-bib-0029){ref-type="ref"}).

In the AMKL study cohort reported by Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"})*,* patients were divided into early‐onset (*N *=* *41, 0--4 years) and late‐onset (*N *=* *3, 12--13 years), and fusion genes, namely *CBFA2T3‐GLIS2*,*NUP98‐KDM5A*,*RBM15‐MRTFA*,*KMT2A‐MLLT3* and *KMT2A‐MLLT10*, were only present in early‐onset patients. Comparing *CBFA2T3‐GLIS2*‐positive (*N* = 12) and ‐negative (*N* = 32) patients, all positive patients were early‐onset, i.e. aged 0--4 years, whereas negative patients reflected the bimodal distribution that characterizes the age of AMKL patients. Additionally, 7 out of 12 early‐onset *CBFA2T3‐GLIS2* fusion‐positive patients were infants (\<1 year) (58%), confirming data previously reported by our group (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}, [2014](#bjh15725-bib-0029){ref-type="ref"}).

In the study cohort reported by De Rooij *et al* ([2016](#bjh15725-bib-0009){ref-type="ref"})*,* median age at diagnosis was 1·5 years, similar to the other paediatric AMKL cases, but all of the *CBFA2T3‐GLIS2*‐positive patients were aged \<4 years, whereas other recurrent mutations were associated with a wider age‐range at diagnosis. *CBFA2T3‐GLIS2* is more common in younger patients not only in non‐DS‐AMKL, but also in paediatric *de novo* non‐AMKL CN‐AML (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}).

No significant differences were found between fusion‐positive and fusion‐negative AMKL paediatric patients in terms of leucocyte count at diagnosis, but, in AMKL, *CBFA2T3‐GLIS2*‐positive patients tended to have a higher percentage of bone marrow blasts at diagnosis compared to fusion‐negative patients (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}).

Extramedullary involvement is more frequent in patients expressing the *CBFA2T3‐GLIS2* chimeric gene (25%) compared to the frequency reported for paediatric AML in general (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; Pession *et al*, [2013](#bjh15725-bib-0033){ref-type="ref"}). In some of these cases, extramedullary involvement can be initially confused with a non‐haematopoietic tumour, especially in the presence of cranial bone, ribs and lumbosacral column involvement. To better characterize the molecular and clinical features of AMKL patients, Thiollier *et al* ([2012](#bjh15725-bib-0037){ref-type="ref"}) developed a xenotransplantation model in which human AMKL cells were injected into immunodeficient mice. Mice injected with *CBFA2T3‐GLIS2*‐positive cells (AMKL7) presented spleen nodular infiltration, a finding not observed in animals transplanted with AMKL blasts not carrying this fusion gene. Recipients of *CBFA2T3‐GLIS2*‐positive cells also more frequently showed macroscopic focal spinal cord infiltration of megakaryoblastic cells and cerebral leptomeningeal infiltrates. In one case, primary, secondary and tertiary recipients of AMKL7 cells showed hind leg paralysis and abnormal magnetic resonance imaging signals suggestive of leukaemia spinal cord infiltration (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}). In our case series of fusion‐positive patients, we also found central nervous system involvement more likely than in fusion‐negative patients, but this does not seem to affect the prognosis (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; Creutzig *et al*, [2017](#bjh15725-bib-0006){ref-type="ref"}).

Morphological characteristics of patients with the *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0008}
==============================================================================

Bone marrow smears of *CBFA2T3‐GLIS2*‐positive patients show morphological features of the different FAB subtypes. No specific morphological aspects associated with the fusion gene have been documented. In AMKL *CBFA2T3‐GLIS2*‐positive patients, megakaryoblasts are the predominant component of the blast population in bone marrow and/or peripheral blood. These are markedly pleomorphic, ranging from small, round cells with scanty cytoplasm and inconspicuous nucleoli, resembling haematogones, to large cells with abundant cytoplasm and prominent nucleoli. They often display cytoplasmic blebs or pseudopods and may appear in clusters mimicking metastatic tumours.

In an Italian paediatric cohort, 50% (*N* = 10) of the fusion‐positive patients had a non‐FAB M7 subtype, distributed as follows: M5 15%, M0 15%, M1 10%, M2 5%, M4 5% (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). No morphological differences were found compared to the AML *CBFA2T3‐GLIS2*‐negative FAB counterpart (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}).

Immunophenotypic characteristics of patients with the *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0009}
=================================================================================

The *CBFA2T3‐GLIS2* fusion oncogene is associated with a distinct immunophenotype characterized by overexpression of CD56 (NCAM1) and under‐expression of both HLA‐DR and CD38, similar to the one described as RAM phenotype (Eidenschink Brodersen *et al*, [2016](#bjh15725-bib-0011){ref-type="ref"}). It has been demonstrated, through immunophenotypic analysis combined with morphological, genetic and clinical features, that the RAM phenotype (bright CD56 expression at minimum 2 log10 units greater than normal myeloid progenitors, dim‐to‐negative expression of CD45 and CD38, and lack of HLA‐DR) is a unique entity, distinct from CD56+ non‐RAM and CD56‐negative leukaemias. This phenotype has been associated with younger age, high rate of induction failure and poor outcome (Eidenschink Brodersen *et al*, [2016](#bjh15725-bib-0011){ref-type="ref"}). Interestingly, the RAM phenotype is more prevalent in FAB M7 patients (Eidenschink Brodersen *et al*, [2016](#bjh15725-bib-0011){ref-type="ref"}).

These results suggested that, although *CBFA2T3‐GLIS2*‐positive patients are not identifiable by morphology or cytogenetics, a large portion of them can be detected by flow‐cytometry thanks to the combination of CD56/HLA‐DR/CD38, CD56/HLA‐DR and CD56/CD38 (Eidenschink Brodersen *et al*, [2016](#bjh15725-bib-0011){ref-type="ref"}).

Analysing the distinct gene expression profile of *CBFA2T3‐GLIS2* fusion‐positive samples, Thiollier *et al* ([2012](#bjh15725-bib-0037){ref-type="ref"}) observed that the surface marker CD56 presented a mean differential expression of 35‐fold by microarray and \>200‐fold by RNA‐seq. Flow‐cytometry analysis revealed that *CBFA2T3‐GLIS2*‐positive AMKL blasts were CD41+CD56+ and that CD56 was significantly more expressed than on *NUP98‐KDM5A*‐expressing AMKL leukaemia cells (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}).

Using ChIP, our group showed a significant enrichment of CBFA2T3‐GLIS2 fusion protein on the *NCAM1* (*CD56*) promotor, confirming that *CBFA2T3‐GLIS2* directly regulates the expression of CD56 (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}).

Future prospective studies are warranted to definitively validate the role of flow‐cytometry for identifying children with *CBFA2T3‐GLIS2*--positive AML; in particular, these investigations should have the goal to assess whether the combination of bright expression of CD56 with low to negative expression of HLA‐DR and/or CD38 enables a faster and reliable identification of *CBFA2T3‐GLIS2*‐positive patients.

Clinical outcome of patients with the *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0010}
=================================================================

In almost all of the case series reported so far, the presence of the *CBFA2T3‐GLIS2* fusion transcript is associated with a worse outcome as compared to fusion‐negative AML paediatric patients (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}; Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}).

Historically, non‐DS‐AMKL has a poorer outcome when compared to other AML subtypes, with survival rates ranging between 15% and 50% (Creutzig *et al*, [2005](#bjh15725-bib-0005){ref-type="ref"}; Inaba *et al*, [2015](#bjh15725-bib-0021){ref-type="ref"}; Schweitzer *et al*, [2015](#bjh15725-bib-0036){ref-type="ref"}), but the prognostic impact of specific cytogenetically (Inaba *et al*, [2015](#bjh15725-bib-0021){ref-type="ref"}) and molecularly defined subgroups in AMKL has been better clarified only in the last few years (De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}). Recent studies reporting the clinical outcome of non‐DS‐AMKL children according to the different specific recurrent genetic abnormalities showed that *CBFA2T3‐GLIS2* has the strongest negative impact on patient outcome (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}, [2017](#bjh15725-bib-0010){ref-type="ref"}), with the 5‐year probability of overall survival (OS) ranging between 15 and 30% (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}, [2017](#bjh15725-bib-0010){ref-type="ref"}). This is mainly due to the high frequency of non‐response to induction therapy (primary induction failure, PIF) and cumulative incidence of relapse (CIR) (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}). The presence of *CBFA2T3‐GLIS2* was shown to confer a cumulative incidence of either relapse or non‐response of 86% and was the highest among non‐DS‐AMKL when compared with other genetic subgroups (De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}). In our cohort of Italian children, the evaluation of response to initial therapy by multidimensional flow‐cytometry showed that majority of fusion‐positive patients continued to have detectable disease (i.e. minimal residual disease) at the end of induction treatment (R. Masetti, unpublished data), which resulted in a CIR of around 50% (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). In the same cohort of children, the time elapsing between diagnosis and relapse was a median of 13·9 months (range, 3·2--38·7); of the nine recurrences recorded in this cohort, seven involved the bone marrow and two both the bone marrow and an extramedullary site.

The largest collaborative effort conducted by different groups across Europe (Italian Association of Paediatric Haematology and Oncology, Berlin‐Frankfurt‐Munster Study Group, Dutch Childhood Oncology Group, Saint Louis Hospital) and the Children\'s Oncology Group in the US (De Rooij *et al*, [2016](#bjh15725-bib-0009){ref-type="ref"}) evaluated the outcome of non‐DS‐AMKL associated with different recurrent genetic lesions; patients expressing *CBFA2T3‐GLIS2* showed a 4‐year probability of OS and event‐free survival (EFS) of 38 ± 10% and 33 ± 10%, respectively, with a CIR of 42 ± 10%. The small difference between OS and EFS probability of children with *CBFA2T3‐GLIS2* fusion transcript indicates that, once relapsed, these patients have a dismal chance of rescue. This outcome was not significantly different from that of *NUP98‐KDM5A*‐positive patients (36 ± 13%, 36 ± 13% and 36 ± 14% respectively), and from that of patients harbouring *KMT2A*‐rearrangements (33 ± 13%, 34 ± 13% and 51 ± 15% respectively). All of these three subgroups showed a significantly poorer outcome than that of patients expressing *RBM15‐MRTFA* and of patients without translocations (their 4‐year probability of OS, EFS and CIR being 70 ± 5% *P* = 0·0013, 62 ± 5% *P* ≤ 0·0001 and 19 ± 4% *P* = 0·003, respectively) (Table [2](#bjh15725-tbl-0002){ref-type="table"}).

###### 

Prognostic and patients feature of non‐DS‐AMKL with *CBFA2T3‐GLIS2*,*NUP98‐KDM5A*, and *KMT2A* rearrangements

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                               Group/treatment protocol   Variable           Frequency (%)     Age at diagnosis, median (range)   OS               EFS
  ------------------------------------------------------------------------------------------------------- -------------------------- ------------------ ----------------- ---------------------------------- ---------------- ----------------
  Gruber *et al* ([2012](#bjh15725-bib-0016){ref-type="ref"})                                             SJRH                       *CBFA2T3‐GLIS2*\   13/48 (27%)\      1·5 (0·6--4·7)\                    5 years 28%\     N/A\
                                                                                                                                     *NUP98‐KDM5A*\     4/48 (8·3%)\      N/A\                               N/A\             N/A\
                                                                                                                                     *KMT2Ar*           N/A               N/A                                N/A              N/A

  De Rooij *et al* ([2013](#bjh15725-bib-0008){ref-type="ref"})                                           DCOG                       *CBFA2T3‐GLIS2*\   13/105 (12·3)\    1·4 (0·6--3·4)\                    5 years 19%\     5 years 35%\
                                                                                                                                     *NUP98‐KDM5A*\     11/105 (10·5%)\   1·8 (0·9--4·8)\                    5 years 22%\     5 years 22%\
                                                                                                                                     *KMT2Ar*           13/96 (13·5%)     1·8 (0·7--12)                      5 years 27%      5 years 28%

  Masetti *et al* ([2013a](#bjh15725-bib-0027){ref-type="ref"})[\*](#bjh15725-note-0006){ref-type="fn"}   AIEOP 2002/01 AML trial    *CBFA2T3‐GLIS2*\   20/237 (8·4%)\    1·9 (0·5--4)\                      N/A\             5 years 27·4%\
                                                                                                                                     *NUP98‐KDM5A*\     N/A\              N/A\                               N/A\             N/A\
                                                                                                                                     *KMT2A*            N/A               N/A                                N/A              N/A

  De Rooij *et al* ([2016](#bjh15725-bib-0009){ref-type="ref"})                                           AIEOP\                     *CBFA2T3‐GLIS2*\   24/153 (16%)\     1·5 (0·5--4·0)\                    4 years 38·6%\   4 years 33%\
                                                                                                          I‐BFM/DCOG/SLH\            *NUP98‐KDM5A*\     14/193 (9%)\      1·9 (0·8--8·5)\                    4 years 36%\     4 years 36%\
                                                                                                          COG                        *KMT2Ar*           14/193 (9%)       1·9 (0·7--12·0)                    4 years 33%      4 years 34%

  Hara *et al* ([2017](#bjh15725-bib-0018){ref-type="ref"})                                               JCACS AML99 trial\         *CBFA2T3‐GLIS2*\   12/44 (27%)\      0 (0--2)\                          4 years 41·7%\   4 years 16·7%\
                                                                                                          JPLSG AML‐05 trials        *NUP98‐KDM5A*\     4/44 (9%)\        N/A\                               4 years 50%\     5 years 25%\
                                                                                                                                     *KMT2Ar*           3/44 (7%)         N/A                                N/A              N/A

  De Rooij *et al* ([2017](#bjh15725-bib-0010){ref-type="ref"})                                           Multiple Institutions      *CBFA2T3‐GLIS2*\   16/87 (18%)\      1·3 (0·5--2·8)\                    5 years 14%\     5 years 8%\
                                                                                                                                     *NUP98‐KDM5A*\     10/87 (11·5%)\    2·6 (1·1--8·5)\                    5 years 35%\     5 years 27%\
                                                                                                                                     *KMT2Ar*           15/87 (17·2%)     2·5 (0·7--7·4)                     5 years 27%      5 years 25%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIEOP, Italian Association of Paediatric Haematology and Oncology (Associazione Italiana Ematologia Oncologia Pediatrica); COG, Children\'s Oncology Group; DCOG, Dutch Childhood Oncology Group; I‐BFM, International Berlin‐Frankfurt‐ Munster‐Study Group; JCACS, Japanese Childhood AML Cooperative Study;JPLSG, Japanese Paediatric Leukaemia/Lymphoma Study Group; *KMT2Ar*:*KMT2A* rearrangements; N/A, not applicable; non‐DS‐AMKL; non‐Down syndrome acute megakaryoblastic leukaemia;SJRH, St. Jude Children\'s Research Hospital; SLH, Saint Louis Hospital.

This research paper analysed only normal karyotype patients.

John Wiley & Sons, Ltd

In a previously published study evaluating 40 non‐DS‐AMKL children treated at multiple centres with different treatment approaches, Gruber *et al* ([2012](#bjh15725-bib-0016){ref-type="ref"}) reported a significantly worse 5‐year OS of *CBFA2T3‐GLIS2*‐positive patients as compared to patients with AMKL lacking this chimeric transcript (28·1% vs. 41·9%; *P* = 0·05). Similar results were obtained when the analysis was restricted to 19 non‐DS‐AMKL patients from St. Jude Children\'s Research Hospital, with a 5‐year OS of 34·3% and 88·9% for *CBFA2T3‐GLIS2*‐positive and ‐negative patients, respectively (*P* = 0·03) (Gruber *et al*, [2012](#bjh15725-bib-0016){ref-type="ref"}).

The most recent Japanese AML99 and AML‐05 experience showed a significantly lower 4‐year EFS and a worse CIR for fusion‐positive than fusion‐negative patients (EFS: 16·7% vs. 44·1% *P* = 0·068; CIR: 70·0% vs. 35·7% *P* = 0·024 respectively) (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}). Interestingly, six (86%) out of seven *CBFA2T3‐GLIS2*‐positive infants relapsed and all the *CBFA2T3‐GLIS2*‐positive patients with PIF were infants, suggesting that fusion‐positive infants may have an even worse prognosis than older fusion‐positive paediatric patients (Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}). The molecularly defined subgroup of patients carrying the *DHH‐RHEBL1* fusion transcript among the *CBFA2T3‐GLIS2*‐positive patients (Masetti *et al*, [2013b](#bjh15725-bib-0028){ref-type="ref"}) seems to be associated with a particularly dismal outcome, although this finding has to be confirmed in a larger cohort of patients. The published case series of *CBFA2T3‐GLIS2*‐positive patients are not sufficiently large enough to clarify if there are any additional clinical or molecular risk factors predicting outcome.

The poor outcome was confirmed also in *CBFA2T3‐GLIS2* patients with AML (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}). In the Italian cohort (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}), the probability of EFS was lower for fusion‐positive non‐M7 patients as compared to fusion‐negative non‐M7 patients (30·0% vs. 59·4%, *P* = 0·04), this suggesting that the grim prognosis conferred by the presence of the fusion transcript is not influenced by the FAB group (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}).

In light of all these findings, *CBFA2T3‐GLIS2*‐positive patients are currently allocated to the high‐risk group of many paediatric treatment protocols and are considered candidates to receive allog‐HSCT‐ in first complete remission (CR1). Although there is clear evidence that allo‐HSCT has a greater anti‐leukaemic potential than chemotherapy as post‐remission treatment, its role for children with AML in CR1 is still debated (Hasle, [2014](#bjh15725-bib-0019){ref-type="ref"}; Zwaan *et al*, [2015](#bjh15725-bib-0044){ref-type="ref"}). Despite the lack of robust data showing an undisputable advantage for *CBFA2T3‐GLIS2*‐positive patients given an allograft in CR1, it is reasonable to speculate that, after achieving remission, a consolidation approach including allo‐HSCT could be the best strategy to avoid recurrence (De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}; Hara *et al*, [2017](#bjh15725-bib-0018){ref-type="ref"}).

Targeting opportunities for patients with the *CBFA2T3‐GLIS2* fusion gene {#bjh15725-sec-0011}
=========================================================================

Given the grim prognosis of *CBFA2T3‐GLIS2*‐positive patients, it is clear how much this leukaemia subgroup needs new, targeted therapeutic approaches. Nowadays, a deeper knowledge of the expression pathways induced by the fusion gene opens new potential therapeutic strategies (Fig [4](#bjh15725-fig-0004){ref-type="fig"}).

![Potential therapeutic target proposed to block leukaemia properties induced by the presence of CBFA2T3‐GLIS2. Aurora Kinase A (AURKA) inhibitors repress proliferation interfering with cell cycle and engages terminal differentiation of megakaryoblastic leukaemia cells (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}). Small peptides, such as NC128, interfere with the NHR2 domain of CBFA2T3 moiety disrupting the complex and abrogating growth of AMKL cells *in‐vivo* (Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}). Treatment with GLI inhibitors interferes with expression pathway induced by CBFA2T3‐GLIS2. The specific interaction between GANT61 and GLIS2 remains to be formally demonstrated (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}). DiMF, dimethylfasudil.](BJH-184-337-g004){#bjh15725-fig-0004}

As early as 2012, the efficacy of Dimethylfasudil (DiMF) was demonstrated in the treatment of AMKL, particularly AMKL with *CBFA2T3‐GLIS2* (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}). In particular, DiMF, an inhibitor of Aurora kinase A (AURKA), was shown to efficiently induce differentiation and polyploidization of leukaemia blasts and drastically inhibited proliferation *in‐vitro* (Wen *et al*, [2012](#bjh15725-bib-0042){ref-type="ref"}). In addition, *in‐vivo* treatment with AURKA inhibitor of mice xenografted with human AMKL cells bearing the *CBFA2T3‐GLIS2* fusion significantly reduced the disease burden and prolonged survival of the mice (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}) (Fig [4](#bjh15725-fig-0004){ref-type="fig"}).

Another attractive target is the protein complex recruited by the fusion described by Thirant *et al* ([2017a](#bjh15725-bib-0038){ref-type="ref"}). In particular, it is known that ETO proteins depend on the NHR2 domain for their ability to oligomerize and recruit co‐factors and can be inhibited by the expression of a peptide called NC128, which contains the NHR2 domain (Wichmann *et al*, [2007](#bjh15725-bib-0043){ref-type="ref"}). Indeed, NC128 expression in cell lines and *CBFA2T3‐GLIS2* blasts derived from AMKL patients decreased proliferation, reduced cell‐cycle progression and increased cell death, and was associated with significant down‐regulation of *ERG* and up‐regulation of *GATA1* expression *in‐vitro* and *in‐vivo* (Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}) (Fig [4](#bjh15725-fig-0004){ref-type="fig"}). These data support the concept that the NHR2 domain is essential for the establishment of *CBFA2T3‐GLIS2* transcriptional alterations and for the *in‐vivo* maintenance of human *CBFA2T3‐GLIS2*‐expressing AMKL cells. In recent years, our group has been working to specifically counteract the leukaemia‐promoting effect of the fusion gene by inhibiting its binding to DNA through targeting of the GLIS2 zinc finger domain (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}). Indeed, the GLIS2 protein shares a highly homologous zinc finger domain with members of the GLI proteins (Vasanth *et al*, [2011](#bjh15725-bib-0040){ref-type="ref"}).

GLI family proteins are the final effectors of the classic Hedgehog pathway, and some preclinical studies provided evidence of the inhibition of their activity by some molecules (Pan *et al*, [2012](#bjh15725-bib-0032){ref-type="ref"}; Agyeman *et al*, [2014](#bjh15725-bib-0001){ref-type="ref"}; Wellbrock *et al*, [2015](#bjh15725-bib-0041){ref-type="ref"}).

The GLI inhibitor GANT61 is a small molecule that inhibits DNA binding of GLI family proteins, and it is mainly used in preclinical studies (Pan *et al*, [2012](#bjh15725-bib-0032){ref-type="ref"}; Wellbrock *et al*, [2015](#bjh15725-bib-0041){ref-type="ref"}). Considering the high homology of the DNA‐binding domain between GLIS2 and GLI family proteins, we hypothesized that GANT61 might be used to specifically target the *CBFA2T3‐GLIS2* fusion in childhood AML (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}). Experimental results showed that, after exposure to GANT61, both cell lines and primary AML cells carrying *CBFA2T3*‐*GLIS2* showed a higher sensitivity to undergo apoptosis and to display G1 cell‐cycle arrest than AML cells without the *GLIS2* fusion (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}) (Fig [4](#bjh15725-fig-0004){ref-type="fig"}). Moreover, GANT61 treatment induced down‐regulation of some genes directly regulated by the fusion gene, including *ERG*,*GATA3*,*DNMT1* and *DNMT3B*, suggesting the specificity of GANT61 treatment to block the DNA binding (Masetti *et al*, [2017](#bjh15725-bib-0030){ref-type="ref"}). Although further studies are required to confirm these results, it is reasonable to hypothesize that inhibition of GLIS2 transcription activity could represent a valid therapeutic approach for targeting *CBFA2T3*‐*GLIS2* positive leukaemia and for improving the dismal outcome of young children carrying this peculiar molecular lesion (Fig [4](#bjh15725-fig-0004){ref-type="fig"}).

Conclusion {#bjh15725-sec-0012}
==========

*CBFA2T3‐GLIS2* represents one of the most important, recently identified, recurrent molecular lesions in the evolving molecular landscape of paediatric AML. Its discovery significantly contributed to re‐categorize the heterogeneous scenario of paediatric non‐DS AMKL. Moreover, as this fusion transcript has been found in non‐M7 patients, we suggest extending the screening of this fusion to all newly diagnosed children below the age of five and not showing recurrent molecular lesions typical of paediatric AML. Given that conventional karyotyping will not reveal cryptic translocations like *CBFA2T3‐GLIS2*, this should be included in the panel of routinely screened aberrations through a reverse transcription polymerase chain reaction approach using specific primers (Masetti *et al*, [2013a](#bjh15725-bib-0027){ref-type="ref"}).

The relevance of *CBFA2T3‐GLIS2* for paediatric haematologists is not only related to its frequency or to the fact that this characterizes a specific leukaemia entity of childhood. In fact, given that *CBFA2T3‐GLIS2* positive leukaemia is an extremely aggressive disease, the detection of this lesion is of paramount importance for the proper risk‐based allocation of patients in future clinical trials. Most of the patients harbouring *CBFA2T3‐GLIS2* present with a resistant disease and have a high propensity to relapse; thus, allocation of patients to high‐risk treatment and use of HSCT in consolidation therapy are strongly recommended. The contribution to leukaemogenesis of the cryptic fusion transcript has been gradually elucidated over recent years (Thiollier *et al*, [2012](#bjh15725-bib-0037){ref-type="ref"}; De Rooij *et al*, [2017](#bjh15725-bib-0010){ref-type="ref"}; Thirant *et al*, [2017a](#bjh15725-bib-0038){ref-type="ref"}) and it has been speculated that this aberration could represent an attractive option for targeted, more effective therapies. This approach is more than desirable, in a context such as paediatric AML, in which, despite the use of intensive chemotherapy and allogeneic HSCT, the survival rate so far is still unsatisfactory.
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